Magnesium valproate has been shown to halt disease progression in the early stages of diabetic cardiomyopathy, potentially through the upregulation of estrogen receptors in left ventricle (LV) tissue (Rabadiya et al., 2018). The gene discussed is ESR1; the disease is diabetic cardiomyopathy.